In Patients with a Peri-procedural Cerebral Thromboembolism, Does Neurovascular Rescue Improve Clinical Outcome?

Background:Quality of life (QoL) is considered an important outcome in the treatment of schizophrenia and is linked with clinical and social recovery. Until recently treatments of schizophrenia have focused mainly on reducing positive symptoms, often leaving patients with numerous residual difficulties. It's been expected that atypical antipsychotics improve QoL equally as they improve clinical outcome of the patients with schizophrenia.Objectives:To compare clinical improvement and QoL of patients treated with risperidone and clozapine two months after the beginning of treatment.Methods:The sample included 40 patients (17 males and 23 females, mean age 33.1) with diagnosis of schizophrenia according to ICD-X. the patients were treated with either risperidone (n=20) or clozapine (n=20). the PANSS and CGI scales for clinical status were applied at the beginning of the treatment and two months later. the QoL was assessed by the WHOQOL-BREF.Results:Analysis of data has shown a significant difference for all four domains (physical, psychological, social relationships and environment) at WHOQOL-BREF scale for both medications after two months, but no difference between the two antipsychotics. the patients treated with clozapine had significantly higher scores on PANSS at the beginning of treatment. PANSS and CGI applied after two months have not shown differences between the medications.Conclusion:Both clozapine and risperidone had equal and statistically significant effect in reducing the symptoms of schizophrenia measured by PANSS and CGI in two months period, as well as in improving the quality of life. However no difference was found between the two medications.

Download Full-text

Tailoring Antiplatelet Therapy: A Step Toward Individualized Therapy to Improve Clinical Outcome?

Current Pharmaceutical Design ◽

10.2174/138161212803251934 ◽

2012 ◽

Vol 18 (33) ◽

pp. 5392-5401

Author(s):

Marc Laine ◽

Laurence Camoin-Jau ◽

Jacques Bessereau ◽

Armero Sebastien ◽

Franck Paganelli ◽

...

Keyword(s):

Clinical Outcome ◽

Antiplatelet Therapy ◽

Individualized Therapy ◽

Improve Clinical Outcome

Download Full-text

Methylprednisolone Therapy of Deceased Donors Could Improve Clinical Outcome after Kidney Transplantation

Transplantation Journal ◽

10.1097/00007890-201211271-01611 ◽

2012 ◽

Vol 94 (10S) ◽

pp. 823

Author(s):

P. Warnick ◽

W. Faber ◽

A. Pascher ◽

M. Bahra ◽

J. Hörstrup ◽

...

Keyword(s):

Kidney Transplantation ◽

Clinical Outcome ◽

Deceased Donors ◽

Improve Clinical Outcome

Download Full-text

P3583Optimal procedural strategy to improve clinical outcome in primary percutaneous coronary intervention

European Heart Journal ◽

10.1093/eurheartj/ehz745.0443 ◽

2019 ◽

Vol 40 (Supplement_1) ◽

Author(s):

Y J Park ◽

J H Lee ◽

B E Park ◽

H N Kim ◽

S Y Jang ◽

...

Keyword(s):

Percutaneous Coronary Intervention ◽

Clinical Outcome ◽

Confidence Interval ◽

Antiplatelet Agents ◽

Coronary Intervention ◽

Thrombus Aspiration ◽

Percutaneous Coronary ◽

Procedural Strategy ◽

Transradial Intervention ◽

Improve Clinical Outcome

Abstract Background Current guideline recommends potent antiplatelet agents and transradial intervention. However, it is uncertain whether routine use of IVUS, thrombus aspiration and glycoprotein IIB-IIIA inhibitor is beneficial for improving clinical outcome in patients with ST-segment elevation myocardial infarction (STEMI). Purpose The aim of this study was to investigate optimal procedural strategy to improve clinical outcome. Methods A total of 6,046 patients who underwent primary percutaneous coronary intervention (PCI) for STEMI were analyzed from the Korean Acute Myocardial Infarction Registry (KAMIR) – National Institute of Health (NIH) database. MACCEs were defined as a composition of all cause death, non-fatal MI, repeat revascularizations including repeated percutaneous coronary intervention and coronary bypass grafting, cerebrovascular accident and rehospitalizations. This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention. Results During the primary PCI, potent antiplatelet agents such as prasugrel and ticagrelor were used in 2342 (38.4%). PCI was performed through transradial approach in 1490 (25.2%). Thrombus aspiration and intravascular ultrasound (IVUS) examination was done in 2204 (36.1%) and 1079 (18.1%), respectively. Glycoprotein IIB-IIIA inhibitor was administered in 1295 (21.7%). Among them, potent antiplatelet agents, transradial intervention, IVUS, and thrombus aspiration significantly reduced MACCEs at 1 year. Glycoprotein IIB-IIIA inhibitor was not effective to improved clinical outcome. In Cox-proportional hazards model, potent antiplatelet agents (hazard ratio 0.82, 95% confidence interval 0.67–0.99; p=0.045) and transradial intervention (hazard ratio 0.61, 95% confidence interval 0.47–0.78; p<0.001) was an independent predictor of MACCEs after adjusting for confounding variables. Combined use of potent antiplatelet agents and transradial intervention (hazard ratio 0.54; 95% confidence interval 0.37–0.80; p=0.002) substantially reduced MACCEs at 1 year. Conclusion Among evidence based procedures during the primary PCI, combined use of potent antiplatelet agents and transradial intervention was optimal procedural strategy to improve clinical outcome.

Download Full-text